|
Brain
Tumors
|
|
|
Yanli Zhuang, Charles
H. Fraga, K. Elaine Hubbard, Nikolaus Hagedorn,
John C. Panetta, Christopher M. Waters and Clinton
F. Stewart
Topotecan Central Nervous System
Penetration Is Altered by a Tyrosine Kinase Inhibitor
Cancer Research 66, 11305-11313, December 1, 2006. doi:
10.1158/0008-5472.CAN-06-0929
|
|
|
|
Glioblastoma
|
|
|
A. Chakravarti, W. Seiferheld,
H. I. Robins, A. Guha, D. Brachman, W. Curran, A. Choucair, M. Mehta
An update of phase I data from RTOG 0211: A
phase I/II clinical study of gefitinib+ radiation for newly-diagnosed
glioblastoma (GBM) patients
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1571 (Clinical
Study)
|
|
A. Das, M. Badruddoja,
D. Tryciecky, J. Yu and K. Black
Phase I study of gefitinib and rapamycin
in patients with recurrent or progressive glioblastoma (Gbm)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1572. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1572
|
|
T.
S. Peery, D. A. Reardon, J. Quinn, J. Ochs, C. Wikstrand, T. T. Stenzel, D.
D. Bigner, H. S. Friedman, J. N. Rich, J. Dancey
Phase II trial of ZD1839 for patients with first
relapse glioblastoma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 396 (Clinical Study)
|
|
M.
Raphael Pfeffer, Mark L. Levitt, Dan Aderka
Gefitinib
in Recurrent Glioblastoma
Journal of Clinical
Oncology, Vol 22, No 13 (July 1), 2004: pp. 2755. (Correspondence, HTML
& PDF Full
Text)
|
|
Jeremy
N. Rich, Henry S. Friedman, James B. Powell, Jr,
Janet E. Dancey
In
Reply
Journal of Clinical
Oncology, Vol 22, No 13 (July 1), 2004: pp. 2755-a-2756. (Correspondence,
HTML & PDF Full
Text)
|
|
Jeremy N. Rich, David
A. Reardon, Terry Peery, Jeannette M. Dowell,
Jennifer A. Quinn, Kara L. Penne, Carol J.
Wikstrand, Lauren B. Van Duyn, Janet E. Dancey,
Roger E. McLendon, James C. Kao, Timothy
T. Stenzel, B.K. Ahmed Rasheed, Sandra E.
Tourt-Uhlig, James E. Herndon, II, James J.
Vredenburgh, John H. Sampson, Allan H. Friedman,
Darell D. Bigner, Henry S. Friedman
Phase II Trial of Gefitinib in Recurrent
Glioblastoma
Journal of Clinical Oncology, Vol 22, No 1 (January 1), 2004: pp. 133-142 (Clinical
Study, Abstract & PDF Full Text)
|
|
J. H. Uhm, K. V. Ballman, C.
Giannini, J. C. Krauss, J. C. Buckner, D. James, B. W. Scheithauer, J. R.
O'Fallon, K. A. Jaeckle
Phase II study of ZD1839 in patients with newly
diagnosed grade 4 astrocytoma
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1505 (Clinical
Study)
|
|
|
|
Gliomas
|
|
|
|
Brandes AA, Franceschi E, Tosoni A, Hegi ME,
Stupp R
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and
disappointments
Clin
Cancer Res. 2008 Feb 15;14(4):957-60
 Abstract |
Links | BL 7:12
|
|
Lassman AB, Rossi MR, Razier JR, Abrey LE,
Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ,
Cowell JK, Deangelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland
EC
Molecular study of malignant
gliomas treated with epidermal growth factor receptor inhibitors: tissue
analysis from north american brain tumor consortium trials 01-03 and 00-01
Clin
Cancer Res. 2005 Nov 1;11(21):7841-50. (Clinical Study, Abstract)
|
|
F. S. Lieberman, T. Cloughesy,
H. Fine, J. Kuhn, K. Lamborn, M. Malkin, H. I. Robbins, W. A. Yung, P. Wen,
M. Prados
NABTC phase I/II trial of ZD-1839 for recurrent
malignant gliomas and unresectable meningiomas
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1510 (Clinical
Study)
|
|
F.
S. Lieberman, T. Cloughesy, L. DeAngelis, H. Fine, K. Fink, L. Junck, J.
Kuhn, M. Mehta, P. Wen, M. Prados
Phase
I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas
progressing after radiation therapy
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 421 (Clinical Study)
|
|
Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K,
Delattre JY
EGFR tyrosine kinase domain mutations in human
gliomas
Neurology.
2005 Apr 26;64(8):1444-5. (Laboratory Investigation, Abstract)
|
|
M. Prados, W. Yung, P. Wen, L.
Junck, K. Fink, T. Cloughesy, I. Robins, S. Chang, J. Kuhn
Phase I study of ZD1839 plus
temozolomide in patients with malignant glioma. A study of the North American
Brain Tumor Consortium
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1504 (Clinical
Study)
|
|
Schwer
AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C.
A Phase I Dose-Escalation Study of Fractionated
Stereotactic Radiosurgery in Combination with Gefitinib in Patients with
Recurrent Malignant Gliomas.
Int
J Radiat Oncol Biol Phys. 2007 Oct 29; [Epub
ahead of print]
Abstract
|
|
|
|
Metastatic
Tumors
|
|
|
Lung
Cancer
|
|
|
E.
A. Diaz-Canton, G. Recondo
Non small cell lung cancer (NSCLC) metastatic to
the brain: A cohort study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 462 (Clinical Study)
|
|
Cappuzzo F, Calandri C, Bartolini S, Crino L
ZD
1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC):
report of four cases
Br J Cancer. 2003 Jul 21;89(2):246-7
(Case
Report, Abstract)
|
|
H
Cortes-Funes and H Soto Parra
Extensive
experience of disease control with gefitinib and the role of prognostic
markers
British Journal of Cancer (December 2003) 89 (Suppl 2), S3-S8. (Review
Article, Abstract)
|
|
A Katz
and P Zalewski
Quality-of-life
benefits and evidence of antitumour activity for patients with brain metastases
treated with gefitinib
British
Journal of Cancer
(December 2003)
89 (Suppl 2), S15-S18.
(Case Report, Abstract)
|
|
R
Stahel, A Rossi, L Petruzelka, P Kosimidis, F de Braud, M M Bernardo,
P-J Souquet, H Soto Parra and C Gridelli
Lessons
from the 'Iressa' Expanded Access Programme: gefitinib in special
non-small-cell lung cancer patient populations
British Journal of Cancer (December 89 (Suppl 2), S19-S23.
(Clinical Study, Abstract)
|
|
N
van Zandwijk
Tolerability
of gefitinib in patients receiving treatment in everyday clinical practice
British Journal of Cancer (December 89 (Suppl 2), S9-S14.
(Review Article, Abstract)
|
|
Wu
C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z.
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the
brain.
Lung
Cancer. 2007 Apr 12; [Epub ahead of print]
PMID: 17434236 [PubMed - as supplied by publisher]
|
|
Wu
YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, Zhou Q, Xu CR, Wang Z.
[Gefitinib target treatment in non-small cell lung cancer.]
Zhonghua
Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):98-102. Chinese.
PMID: 17445469 [PubMed - in process]
|
|
|
|
